Company / Operating Cash Flow
Alaunos Therapeutics, Inc. Operating Cash Flow History
FY2012-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
-$5.0M
FY2025
5-year range
-$61.5M / -$5.0M
FY2021-FY2025
Trend
+83.5%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Operating Cash Flow has fluctuated over the past 10 years, ranging from -$61M in FY2022 to -$5M in FY2025.
Based on SEC 10-K filings.
-$5M in FY2025.
Improved from -$29M to -$5M over the past 2 years.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, operating cash flow increased 83.5% year-over-year.
- Lowest operating cash flow in the period was in FY2022.
Company context
Key Data Points
- Altman Z-Score -3.79 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$5.0M | +83.5% |
| FY2024 | -$30.1M | -3.1% |
| FY2023 | -$29.2M | +52.4% |
| FY2022 | -$61.5M | -7.8% |
| FY2021 | -$57.0M | -15.3% |
| FY2020 | -$49.5M | +9.5% |
| FY2019 | -$54.7M | +6.3% |
| FY2018 | -$58.3M | -50.2% |
| FY2013 | -$38.8M | -97.2% |
| FY2012 | -$19.7M | -60.2% |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026